SEARCH

SEARCH BY CITATION

References

  • 1
    Fang GD, Fine M, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69: 307316.
  • 2
    Fass RJ. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993; 32(suppl A): 1727.
  • 3
    The British Thoracic Society London. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346350.
  • 4
    Societé du tethologie Infectieuse de Langue Francaise. Les infections des voies respiratoires. Quatrième Conférence de Consensus Thérapeutique Anti-Infectieuse (18 Octobre 1991, Lille). Résumé Recommend Pressé Med 1991; 20: 22342265 .
  • 5
    American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 14181526.
  • 6
    Ramirez J. Penicillin-resistant pneumococci: new-generation fluoroquinolones and lower respiratory tract infections. Hosp Med 1999; 35: 4349.
  • 7
    Hoellman DB, Lin G, Jacobs MR et al. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999; 43: 645649.
  • 8
    Dubois J, St-Pierre C. An in vitro susceptibility study of gatifloxacin against Legionella spp. Diagn Microbiol Infect Dis 1999; 33: 261266.
  • 9
    Miyashita N, Niki Y, Kishimoto T et al. In vitro and in vivo activities of AM-1155 against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 13311334.
  • 10
    Jones RN, Biedenbach DJ, Erwin ME et al. Activity of gatifloxacin against H. influenzae and M. catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae. J Clin Microbiol 1999; 37: 19992002.
  • 11
    Honeybourne D, Banerjee D, Andrews JM, Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 2001; 48: 6366.
  • 12
    Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593596.
  • 13
    Beam TR, Gilbert DN, Kunin CM, eds. European guidelines for the clinical evaluation of anti-infective drug products. Basel: European Society of Clinical Microbiology and Infectious Diseases, 1993.
  • 14
    Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference of non-unity relative risk. Stats Med 1990; 9: 14471454.
  • 15
    Hollander M, Woolfe DA. Nonparametric statistical methods. New York, NY: Wiley, 1973.
  • 16
    Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 20802084.
  • 17
    Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000; 46: 39.
  • 18
    Bauernfeind A, Schneider I, Miehle S et al. Resistance to gatifloxacin, augmentin, amoxycillin and clarithromycin of pathogens from respiratory tract infections in 16 European countries. In: Program and abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA. Alexandria: IDSA, 1999.
  • 19
    Read R. Infection in acute exacerbations of chronic bronchitis: a clinical perspective. Respir Med 1999; 93: 845850.
  • 20
    Schaberg T, Lode H. Klinik und Diagnostik der ambulant erworbenen Pneumonien. Dtsch Med Wschr 1991; 116: 18771880.
  • 21
    Ramirez J, Nguyen T-H, Tellier G et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Respir Dis 1999; 20(suppl): S40S48.
  • 22
    Gotfried M, Quinn TC, Gothelf S et al. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagn Microbiol Infect Dis 2002; 44: 8591.
  • 23
    Jones RN, Andes DR, Mandell LA et al. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44: 93100.
  • 24
    Nicholson SC, Webb CD, Andriole VT et al. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. Diagn Microbiol Infect Dis 2002; 44: 101107.
  • 25
    Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Respir Dis 1999; 20(suppl): S70S76.
  • 26
    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety 1995; 13: 343358.
  • 27
    Lietman PS. Fluoroquinolone toxicities. An update. Drugs 1995; 49: 159163.